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SUMMARY 
 
This study attempts to analyse potential gender differences 
among a group of heroin addicts seeking treatment at a 
university-based medical center. 
The central modality of treatment at this centre is the use of 
methadone maintenance.  
Using the Self-Report Symptom Inventory (SCL-90), we 
studied the psychopathological dimensions of 1,055 patients 
with heroin addiction (884 males and 171 females) aged 
between 16 and 59 years at the beginning of treatment, and 
their relationship to age, sex and duration of dependence. 
Also we analyse demographic characteristics of 368 heroin 
addicts at first treatment according to gender. 
Among those patients entering this program there seems to 
be an emerging pattern of males who tend to use heroin as 
their opiate of choice, and are more likely to combine it 
with cannabis, while females are more likely to use to street 
methadone, with adjunctive use of ketamine, 
benzodiazepines, hypnotic drugs and/or amphetamines.  
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Women are at higher risk of abusing opioids through a 
pathway of initial prescription painkiller use, and later to 
resort to street methadone to cope with prescription pain 
killer addiction. This latter pattern seems to result in an 
increased risk for fatal accidental overdoses. The use of 
these longer-acting agents in women may be influenced by 
psychosocial and hormonal factors. 
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 INTRODUCTION 
 
Studies of heroin dependent persons have described a 
chronic disorder strongly associated with polydrug use, poor 
mental and physical health, an increased risk for mortality, 
and poor legal, social  and economic outcomes (80, 81, 82; 
83, 84). There is some evidence of different characteristics 
for male and female dependent heroin users. Those studies 
that have reported sex differences found that females were 
younger (85, 86) and had more suicide attempts and fewer 
completed suicides (87, 88); different injecting behaviours 
(89); less education and employment (85); a younger onset 
of heroin use; more dysfunctional families and exposure to 
more unfavourable social factors (85;90); greater health 
service utilization (91; 92); higher standardized mortality 
ratios (93); more psychological problems (90; 94); and were 
more likely to sustain abstinence after treatment (95) than 
men. The evidence regarding sex differences in 
polysubstance use and dependence among heroin users is 
mixed, with one study finding no differences in the number  
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of current or lifetime diagnoses (96), another found higher  
levels of polydrug use amongst male heroin users (97) and  
another finding no sex differences in class memberships 
based on polysubstance use (98). 
Although it is a low prevalence disorder, the severity of 
problems associated with it makes it an important public 
health issue to understand. Further, within the heroin 
dependent population, important clinical differences may 
manifest for different subpopulations including males and 
females. 
 
 
GENDER DIFFERENCES IN SOMATHYC PATHOLOGY 
 
In a recent study one hundred and forty men and women, 
respectively, could be matched regarding age and 
recruitment centre; in this sample, the composite score for 
medical problems was higher in women [0.4 (SD = 0.4)] 
than in men [0.2 (SD = 0.3); t(277) = −3.01; p < 0.01]. (117) 
In men some studies reported major risk of progression of 
HIV and AIDS (12). 
Minor Adherence to antiretroviral treatment was evidenced 
in male heroin dependents(12). 
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In a recent study, where a total of 991 subjects (73% males), 
mean age = 25.7 years were interviewed, when doing the 
analysis with the total sample an interaction between gender 
and HIV infection was found, indicating that positive HIV 
serology only had an impact on Health Related Quality of 
Life (HRQL) of men. (80) 
Some studies have found a slower progression to AIDS 
among HIV positive women, and Jarrin et al say that ―in 
settings with small gaps in gender inequality and universal 
access to care, HIV-infected women fare better than their 
male counterparts in the era of HAART‖(80; 110). 
In women major adverse effects were present in drugs 
utilized to therapy (3) 
Major somatic complication (infections, gastroenteric 
pathologies, muscular-skeleton pathologies, systemic 
complications) also were present in women (3,5,8,27,31,62) 
When we observed HIV relapse after antiretroviral 
treatment, women resulted to have major risk of relapse 
than men. (9) 
Towards the risk HIV sexual transmission female heroin 
dependents were at major risk than men at the same 
condiction (36,54). 
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 In women there was major prevalence of positivity to 
HIV(13,65; 17% vs 11%; 51). 
Related to health, female heroin addicted had major 
impairment of general condition (13,34,47), and also major 
hospitalization. 
 
 
GENDER DIFFERENCES IN PSYCHIATRIC PATHOLOGY 
 
In men as in women some studies didn’t evidenced  
differences in anxiety and major depression(2,17,43,66,68), 
also in dysthimia, double depression, bipolar disorder (43). 
Male heroin addicted presented suicidality related to 
severity of toxicomanic history, aggressiveness, presence of 
PTSD and problem in work (6). 
Major presence of antisocial personality disorder (39), and 
conduct  disturbances (67,70) were present in men.  
No differences in prevalence of other personality disorder 
(77) were evidenced in recent studies.  
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Some studies reported a major presence of ADHD in men 
versus women (43), but in other studies ADHD prevalence 
was similar in women and in men(66). 
 
In women it was reported in many studies that the 
psychiatric symptomatology (5,19,45,59,70,73,74) was 
more  severe than same symptomatology reported in men. 
Axis I disorders were more present in women than in men 
(77). This data was also evidenced in a study conducted 
with the purpose of analyzing gender differences in the 
German trial on heroin-assisted treatment (HAT) which 
compared HAT with methadone maintenance treatment 
(MMT). Significant baseline gender differences were found, 
with females showing a greater extent of mental distress 
(119). 
When we have reaserched differences in mood disorders, it 
was reported that mood disorders were are more present 
than in men; in fact, there was a major incidence of 
depressive symptoms (6,33,39, 52,59, 62,63), dythimia 
(52,68) but also of maniacal symptoms(52) in male addicted 
than female addicted.  Related to mood disorder, in 
literature we reaserched gender differences of the presence 
of suicidality. 
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Results of our research evidenced that elements as past 
sexual and physical abuses, poor social supports and low 
self-esteem were generally related to the presence of 
suicidality (6) in women.  
Females addicted to heroin also had a higher prevalence of 
suicidal thoughts and behaviours than males. A more 
detailed analysis of suicidal behaviours and associated 
characteristics among a sample of a recent study related to 
gender differences was reported elsewhere (100). 
Because of the link evidenced in women between the 
suicidality and past sexual and physical abuses, we 
investigated the relationship between severity of psychiatric 
symptoms and these stressor. A study evidenced that in 
victims of sexual and physical abuse the severity of 
psycopathology was greater than women who didn’t 
(50%>20%) (6). 
So, in female addicted suicidality ideation was major 
present than in male(21); in literature the prevalence of 
women suicidal attemps was reported to be generally 
greater in the personal history (16, 35,73), particulary in 
lifetime history (44% vs 28%), and in the last 12 months  
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(21% vs 9%) (26) than whose reported in men. Major 
suicidality was also reported to women that had cocaine 
addiction (18). 
When we have valuted anxiety disturbances in both gender, 
it was clear that anxiety psychopatology was major present 
in women than in men. 
In fact, the performance anxiety was more (10, 21) reported 
in female addicted than in male addicted; this data was also 
valid for simplex phobies (39, 52) where women had more 
simplex phobies than men. Panic disorders secondary to 
substance abuse was major in women than in men (45) and 
the presence of  Obsessive-Compulsive Disorder also were 
major in female addicted (52). 
Women generally received more pharmacological 
treatments than men. A great number of psychiatric 
complications related to substance abuse were reported in 
female toward those reported in men(27).  
The aggressiveness also was valued in literature.  In some 
studies the presence of aggressiveness wasn’t related to 
gender but to other data as adverse effects of substance 
utilized, sleep disturbances and poor social supports(43). In 
other studies that we analyzed the aggressiveness was   
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related to gender and to risk of treatment’s drop-out (56). 
Eating disorders and PTDS were more present in women 
(32,33,38,39,53,68). 
The prevalence of borderline personality disturbance was 
major in women than in men (39). 
 In a recent study, it was reported that elements as younger 
onset of cannabis use, screening for Bipolar Disorder, the 
presence of major depression, the condiction of heroin 
overdose, sexual abuses, experiencing adult violence and 
having time in prison were associated with a greater number 
of substance dependence diagnoses for males and females 
(79).  
For males, more heroin use per day, antisocial personality 
disorder (ASPD) and post-traumatic stress disorder (PTSD) 
were also associated with multiple substance dependence 
diagnoses (79).  
For females, childhood emotional neglect, suicide attempt/s 
and antisocial behaviour (ASB) were associated with 
increasing substance dependence diagnoses. 
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 GENDER DIFFERENCES IN SOCIAL SITUATION 
 
Health Related Quality of Life (HRQL) has progressively 
been applied in the evaluation of health status of patients, 
including substance users (101, 102, 103). 
Poor HRQL has been reported among heroin users starting 
treatment, being comparable to other chronic disease 
patients (80). 
The more consistent finding was poorer HRQL associated 
with poly-drug use, HRQL has also been related to socio-
demographic variables such as age, educational level or 
employment status, and the presence of chronic medical 
conditions, including HIV infection (101,104,105). 
Although gender has been associated with differences in 
HRQL in many different population studies, being poorer in 
women (106,107), no clear differences have been reported 
in studies on opiate users (101, 104,108,109). 
Familiar supports and quality of life were no different in 
female and in male (32,78). Males were more likely to have 
experienced childhood physical punishment (79). 
In male the prevalence of imprisonment was more 
represented than in female (1). 
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When we reaserched the presence of criminality, we 
evidenced that some studies reported major criminality in 
males (32,45,54,70) than in females. 
On the contrary, other studies reported that the presence of 
criminality in both genders was similar, at the  baseline and 
at follow up (24,29) valutations. Some studies reported that 
males had a longer total time spent in prison and longer 
sentences than females. Addicted males had a higher risk of 
incarceration, criminal activity and arrest, and committed 
different types of crime than females (79).  
Other studies showed the data that men had more legal 
problems regarding incarcerations and they were more often 
living alone or were homeless (117). 
Sexual abuse, emotional abuse and neglect were also 
common. (99). 
Familiar history of alcohol abuse was similar in both 
genders (35,78). 
In literature it was reported a recent study that analyzes 
1513 heroin addicted. In this study  half of the participants 
evidenced that one or both parents had a drug and/or alcohol 
problem.(79) 
When we observed in literature marriage condition, it was  
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evident that male addicted were more singles than female 
addicted (61). 
 
In female conducts at risk were more present than in men 
(prostitution, needle change (1)). Ongoing prostitution was 
found to influence drug use outcomes. (119) 
Condictions as house instability, unemployment, economic 
problems (1,40,41,45,55,64,73), major functional 
compromise situations (7, 27) also were more present in 
female heroin addicted. Several studies have shown that 
interpersonal relationships may have contradictory effects 
for women who were addicts; they could be a source of 
support, but they couls also contribute to ongoing problems 
and possibly relapse (7, 32). 
Women drug users may also be isolated from other sources 
of social support by their partners, particularly if they have a 
history of intimate-partner violence (116) 
Women cohabited more frequently with toxicomanic 
partners (7, 34, 45, 76) than men. 
There were in these female subjects major request of 
assistance for familiar problems, or for traumatic 
experiences (32).  
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Females were more than four times more likely than males 
to have experienced unwanted sexual activity after the age 
of 18, either through the use of physical violence, threats of 
physical violence, blackmail, or the threat of relationship 
break-up (79). 
 Women were also more likely to be victims of adult 
violence (pushing, grabbing, shoving, slapping, hitting, 
kicking, punching, choking, and strangling) or threats of 
violence (hitting, and threatened with a weapon), whilst 
males were more likely to be perpetrators of violence. 
 Females were more likely than males to have had a poor 
relationship with their mother during childhood and 
adolescence, and to experience problematic parental 
substance use, childhood sexual abuse, emotional abuse, 
and emotional neglect (79). 
Males were more likely to have experienced childhood 
physical punishment. 
Lower school- attendance index was present in women 
(35,45); it was valid also for the presence of emigration 
(35), the presence in personal history of sexual, physical, 
psychological abuse (46,62,74,78).  Females were younger 
on average than males, more likely to be married, and to be  
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receiving a government benefit than males, however there 
were no sex differences in unemployment rates or level of 
education (79). 
In women there was a major familiarity for psychiatric 
disease and abuse disorders (44) than in men. 
Problematic families were more present in female (60,71) 
then in males. Women were more coupled than men (61). 
 
 
 
 
 
GENDER DIFFERENCES IN PAST HISTORY OF SUBSTANCE 
ABUSE 
 
Some studies reported that in men as in women the severity 
of past history of Substance Abuse was similar (66). 
Male students of superior school abused more in cannabinoid 
and tobacco than females (14); on contrary, female students 
of inferior school smoke morely than their male same age 
(14). 
In general, cocaine addicted males utilized more money, 
more sedative drugs, more alcohol, and more cannabinoid   
 
 
      15 
(42) than females. 
In women other studies reported a major severity of pregress 
hystory of Substance Abuse (21,22,47), but this date didn’t 
seem to be true for cocaine dependence; in fact it seem that 
the history of cocaine toxicomanic conduct was more brief 
than in male (42). Women had more problems related to 
substance abuse than men(22). In a recent study one hundred 
and forty heroin addicted men and women, respectively, 
could be matched regarding age and recruitment centre; in 
this sample the age at beginning of regular consumption 
(men  mean age 20.55, women mean age 21.4) did not differ 
significantly between both groups (t(242.1) = −1.16; 
p = 0.25) (117). Slightly more males than females had 
experienced a heroin overdose requiring medical treatment.  
There were no sex differences in the experience of multiple 
overdoses (79). A recent study valued 140 addicted males 
and 140 addicted females and their dependence history; in 
this clinical sample, the number of detoxification treatments 
was not different between men and women, but more men 
had been in long-term rehabilitation treatment than women 
(51.9 vs. 17.5%; χ2(9) = 23.73; p < 0.01) (117). 
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 PROXIMAL HISTORY OF SUBSTANCE ABUSE 
 
Analysing the differences of the substance abuse at the 
moment of the first visit, it seem that males utilized more 
benzodiazepines (7), alcohol (54,58), opioid (8, 73), and THC 
(58) towards females. The similarity in both gender was in the 
frequency of the use of substances, (4) but not in the type of 
first substance utilized (40). 
 
Female addicted utilized not only heroin (5) and opioid 
substances (15), but also cocaine (34).  
Differently of males, females asked primarily medical 
treatment and it was valid in particular for complications 
related to substance abuse and not for HIV complications (15). 
Females had generally more insight of disease (15) and they 
were more early than males to request of medical assistance 
(8,72). Moreover, some studies reported that women with 
substance use problems were less likely than men to enter 
treatment over the lifetime (115), and men were more likely to 
be coerced into treatment by external mandates (115). Although 
women might be less likely to enter substance abuse treatment  
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than men over the course of the lifetime, once they enter 
treatment, gender itself was not a predictor of treatment 
retention, completion, or outcome (118). In a recent study the  
relapse to heroin use after a period of abstinence from heroin 
was reported by 83.4% of participants, with males slightly more 
likely than females to have ever relapsed (79).  
No gender differences were observed in the proportion of those 
who had a previous overdose experience or had experienced an 
opiate overdose in the last 12 months before primarily medical 
treatment. (80) 
Women reported worse HRQL, but contrary to males having 
had an opiate overdose, the contact with a psychiatrist or 
having ever been on methadone treatment during the preceding 
12 months were not found to be associated with it (80). 
 
 
 
LONGITUDINAL HISTORY 
 
In literature the age of first drug contact was similar in both 
genders (29,51), so the severity of abuse (20. 35,66,69).  
 
 
      18 
It was different in severity of toxicomanic history 
(11,20,32,63,72,73); in fact males seem to have more severity 
of the history than females. There were no sex differences in 
age of initiation to drug or alcohol use, or in onset of heroin 
dependence. 
Some studies reported that the age of males was later than 
females in the treatment ingress (30,59,74), but other studies 
didn’t evidence this difference (29). In literature it was also 
reported that males had been in treatment for less time and 
sought treatment at an older age than females. 
Addicted males utilized more THC, hallucinogen 
substance(50) and more utilize of endovenous access than 
female addicted (72). 
 Males were more likely than females to receive a lifetime 
diagnosis for cannabis, stimulant or alcohol dependence (79). 
There were no sex differences in the prevalence of sedative, 
cocaine or nicotine dependence.  The most common 
introduction to heroin and its use was through a friend (79). 
However women were more likely than men to be introduced 
to heroin by a partner, boyfriend or spouse, whereas men were 
more likely than women to be introduced to heroin by a friend. 
There were no sex differences in age of initiation to drug or 
alcohol use, or in onset of heroin dependence. 
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 On average, females sought treatment for heroin dependence at 
a younger age than males (79). Onset of cannabis use and first 
alcohol intoxication occurred, on average, at about the same 
age (~14 years) (79). 
Males presented more possibility to have medical assistance 
(30) and they stayed in treatment - as days as ingress in 
treatment- more than females (50). Other studies reported that 
there were no differences in treatments received and in the 
abuse history (76,78) in males and in females. 
When we observed in literature differences in one year of 
follow-up, no differences in both genders there were observed 
in the reduction of substance abuse, health problems and 
criminality problems (34). 
Analysing the female longitudinal history, we evidence in 
literature some interesting date. 
It was observed in fact, in addicted females a major 
progression from abuse to dependence (20,57), a major utilize 
of addictional method of substance abuse (57), a late age of 
exordium (20, 59), a rapid development of organic disease 
(20), a less time intercourse from first use of substance and 
first medical assistance (20,74), a less time of toxicomanic  
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history (20), a major request of treatment independently  by 
physical complications or external intervents (20,48,49) 
towards addicted males. Sex
 
differences were noted in the rate 
of escalation of
 
drug use in which women tend to increase their 
drug intake more
 
rapidly than men. (120) 
In literature was also reported that after treatments women 
reduced the utilize of substance abuse (8). 
 
 
AIM OF RESEARCH 
The aim of our research was to search gender differences 
generally in a sample of 1,090 heroin addicted and into 368 
heroin addicts that were at first treatment. In both samples, the 
data that we valued were demographic characteristics, the 
presence of related somatic diseases (RSD), the mental status 
(Psychophatological Symptoms) refers to symptomatic patients 
and the social adjustment. 
 
MATERIAL  E METHOD 
SAMPLE 
We considered 1,090 heroin addicts who had requested opioid  
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agonist treatment between 1994 and 2005 at the Dual 
Diagnosis Unit of the University Hospital in Pisa, Italy and in 
this sample we analyze 368 heroin addicts at first treatment. 
All patients received a diagnosis of opioid dependence with 
physical dependence (according to DSM III/IIIR/IV criteria) 
and gave their informed consent for study participation.  
Addiction-related information was collected by means of the 
Drug Addiction History Rating Scale (111) administered by a 
psychiatrist. 
The DAH-RS is a multi-scale questionnaire comprised of the 
following categories: demographic data, physical health 
(hepatic, vascular and lymphatic pathology, gastrointestinal 
disorders, sexual disorders, dental pathology, and HIV 
seropositivity), mental health (awareness of illness, memory 
disorders, anxiety disorders, mood disorders, aggression, 
thought disorders, and sensory perception disorders), 
substances abuse (use of alcohol, opiates, central nervous 
system (CNS) depressants, CNS stimulants, hallucinogens, 
phencyclidine, cannabis, inhalants, and polysubstance abuse), 
social adjustment and environmental factors (employment, 
family, gender, socialization and leisure time, and legal 
problems), clinical characteristics as frequency of drug use,  
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patterns of use, phase, nosology, and treatment history 
(previous and current treatments). Items are set up so as to 
elicit dichotomous answers (yes/no).  
Regarding toxicological urinalyses, the enzyme multiplied 
immunotechniques for opiates, methadone, benzodiazepines, 
hypnotics, cocaine, amphetamines, hallucinogens, 
cannabinoids, and inhalants was used. Problematic alcohol use 
was intended as a history of frequent (more than weekly) 
episodes of intoxication, with resultant impairment of working, 
family and interpersonal adjustment, and alcohol-related legal 
trouble. 
 
DATA ANALYSIS 
We compared demographic and clinical features by gender by 
means of the Student t-test for continuous variables and chi-
square test for categories. 
To describe the pattern of substance (ab)use, we used the 
following DAH-RS items: heroin intake (item 57), modality of 
use (item 58), the clinical phase of illness (item 60), presence of 
psychosocial stressors before using heroin (item 61), presence 
or absence of a history of periodic self-detoxifications (item 
59), use of morphine and other painkillers (item 37), heroin 
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(item 36), illegal methadone (item 39), alcohol (item 35), 
ketamine (item 41), benzodiazepines (item 43), hypnotics (item 
44), CNS stimulants (cocaine, amphetamines, Ecstasy—items 
47, 43 and), classic hallucinogens (LSD; item 48), cannabinoids 
(item 53), inhalants (item 54), and polyabuse (item 55). 
Polyabuse was defined as patients abusing heroin and two or 
more other substances. 
A factor analysis was performed on the above-reported abused 
substances for 1,090 patients in order to identify possible 
composite dimensions. The initial factors were extracted by 
means of principal component analysis (type 2) and then rotated 
according to varimax criteria in order to achieve a simple 
structure. This simplification is equivalent to maximising the 
variance of the squared loading in each column. The criterion 
used to select the number of factors was an eingen value greater 
than 1. Item loadings with absolute values greater than 0.4 were 
used to describe the factors. This procedure makes it possible to 
minimise the correlations between the factors, so allowing their 
optimisation as classificatory tools for each subject. In order to 
compare factorial scores, we resorted to a nonparametric test 
(Mann-Whitney), since the score distribution was not a 
Gaussian one. 
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Statistical analyses were carried out using the SPSS package 
(version 4.0 by SPSS Inc). 
As this is an exploratory study, statistical tests were considered 
significant at the p < 0.05 level. 
 
 
 
RESULTS 
SOCIO DEMOGRAPHIC DATA 
We valued socio demographic characteristics of both gender at 
treatment entry. Males and females differed in employment rate 
(37.7% of males were blue collar workers, 37.4% were 
unemployed; 23.9% of females were blue collar workers and 
46.7% unemployed; df = 2; chi-square16.61; p = 0.0002).  
A total of 52.1% of males had blue collar worker parents and 
11.8% unemployed parents, whereas 40.5% of females had blue 
collar worker parents and 17.4% had unemployed parents (df = 
2; chi square 11.92; p = 0.002).  
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A total of 31.5% of males were married versus 47.9% of 
females (df = 1; chi square 23.07; p = 0.0000). 
 
At the first treatment a total of 38.4 males % were blue collar 
workers and 26.6% unemployed, whereas in females a total of 
19.6% were blue collar workers and 40.2% were unemployed 
(chi square 22.63; p=0.00006). Males and females differed also 
in parental occupation; in fact, 48.5% of males had white collar 
worker parents versus 30.2% of females parents. At the first 
treatment, males and females were different in civil status 
(70.8% of males were single vs  60.8% of females). 
In the total sample there weren’t statistically significant 
differences between males and females with regard to age, 
income, education, place of birth or of residence, type of 
housing and whether or not they received public welfare 
benefits at treatment entry. 
When we observed those data at the first treatment, it resulted 
that in females as in males the same place of birth was the same 
place of residence (Central Italy) but there weren’t statistically 
significant differences between males and females with regard  
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to age, income, type of housing and whether or not they 
received public welfare benefits at treatment entry. Regard 
education, there were a significant interruption of studying in 
both gender; in fact 83.6% of males stopped studying,  also 
69.2% of females stopped it. (see Table 1) 
 
 
RELATED SOMATIC DISEASES (RSD) DATA 
 
According to gender, there weren’t any differences in the presence of 
related somatic diseases (RSD); in fact the same percentage of Hepatic, 
Vascolar, Gastrointestinal, Sexual, Dental, Lymphadenitis disease AND  
HIV+ was observed in both gender. The disease more represented was 
hepatic disease ( in males 36.4%, in females 37.5%). For more detailes, 
see Table 2) 
 
MENTAL STATUS DATA 
When we analyzed the Mental Status of 368 heroin addicts at 
first treatment according to gender and specifically the number 
of Psychophatological Symptoms (N°PSYS)  
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 refers to symptomatic patients some interesting data were 
evidenced. 
For the Illness Awareness males resulted to be more aware than 
women (31.6% vs 19.6%) 
On the observation of mood symptoms at the time of the first 
treatment there were also unexpected data; in fact 36.3% of 
addicted males presented depressed mood towards 17.4% of 
females (p=0.055). No statistical significant differences were 
observed in the presence of other mood symptoms as 
Excitement, Violence, Suicidality and  Sleep disturbances. 
Psycothic symptoms as Delusions Hallucination had the same 
prevalence in both genders. 
Males and females had the similar percentage in the presence of 
anxiety symptoms (33.3% vs 42.3%), but they were different in 
the presence of Eating disturbance. Female in fact had more 
Eating Symptoms than men, and this difference was statistical 
significant (19.6% vs 11.6%; p=0.049) 
For more details, see Table 3. 
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 PATTERN OF ABUSE AT TREATMENT ENTRY 
 
Analyzing the history of heroin abuse, when we valued in all 
sample elements as for the frequency of consumption, it was 
evidenced that the majority of treatment-seeking heroin addicts 
used heroin on at least a daily basis. A small minority decided 
to start treatment during periods of weekly or sporadic use.  
No gender-related difference was found with respect to the 
frequency of heroin consumption. 
In the total sample, as for the addictive mode, the majority of 
heroin addicts remained ―stable‖ (maintained a certain level of 
work and social adjustment); one out of five was a ―junkie‖ 
(engaged in violent and disruptive street life). Approximately 
13% swung between social adjustment and disruptive behavior 
(―two-worlders‖), while the smallest minority stuck to the 
―loner‖ mode (avoided dealing with other addicts). 
The great majority of treatment-seeking heroin addicts had 
entered the revolving door phase: it is typical of these addicts to 
be able to stop using heroin from time to time, for periods of 
variable length, between relapses. Ten percent of subjects  
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started using heroin in the context of some form of 
psychosocial stress. The natural history of addiction did not 
vary according to gender. (table 4) 
 
SUBSTANCE ABUSE AT TREATMENT ENTRY  
Regard the utilize of other substances, it was clear that gender 
did not influence the use patterns for opioid painkillers, alcohol, 
cocaine, hallucinogenic drugs, inhalants or for polyabuse. 
Males tended to use heroin as their opiate of choice, and were 
most likely to combine it with cannabis. Females were more 
likely to resort to street methadone, and use ketamine, 
benzodiazepines, hypnotic drugs and amphetamines in addition 
to their drug of choice (heroin). For more detailes, see table 5. 
The factorial analysis (Table 6) defines three dimensions: the 
first (30.7% of variance) corresponds to mixed use of cannabis, 
cocaine and amphetamines, hallucinogenic drugs and alcohol. 
The second (11.7% of variance) corresponds to concurrent 
depressant (benzodiazepine and hypnotics) and painkiller use. 
The third (9.7% of variance) corresponds to addicts who resort 
to anaesthetics (ketamine) and inhalants.  
Of these patterns (Table 4) the first was rather typical of males  
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and the second one of females. No link with gender was found 
for the third. Treatment seeking male heroin addicts, then, were 
more likely to be current polyabusers of all available 
substances. By contrast, female peers quite specifically resorted 
to depressants and painkillers in combination with opiates. The 
male-oriented factor accounts for a rate of variance three times 
greater than the female-oriented factor. 
 
 
DISCUSSION 
 
The few observed psychosocial differences may just mirror 
different roles, with special regard to Italian social stereotypes, 
such as a lower likelihood of women working or have a blue 
collar job (which may not be seen as deviating from the norm in 
female addicts but rather is expected for the general Italian 
female population. As for marital status, women are more likely 
to be married, although mostly to addicted partners. Partners 
may seek treatment independently, but marrying another addict  
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is more typical of females than of males, which makes the 
difference in marital status not necessarily correspondent to 
better psychosocial support or adjustment. 
Although heroin addicts obviously, by definition, engaged in 
heroin consumption, painkiller abuse has been spreading and 
increasing in many countries (112). Our data indicate that 
treatment-seeking male heroin addicts consume greater 
amounts of heroin as a trend (8) while women, contrary to some 
other reports (5) are rather prone to combine smaller amounts 
of heroin with street methadone and prescription painkillers. 
This may mean that women are at higher risk of entering the 
opiate addiction pathophysiology through initial painkiller use, 
and more often resort to illicit methadone treatment to cope 
with painkiller addiction; this pattern presents a higher risk of 
accidental fatalities (113;114). In our subjects, heroin-addicted 
females seemed to switch, at least partially, to opiate analgesics 
as a secondary addictive pattern, possibly coupled with street 
methadone. The clinical meaning of street methadone 
consumption has not been thoroughly investigated, but some 
authors indicate that the use of illegal methadone as drug of 
choice may increase along with the diversion of prescribed 
methadone. 
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In a recent observation we proposed that, at least in Italy, 
resorting to street methadone does not seem to be a surrogate 
form of heroin addiction, but rather represents a type of harm 
reduction, with treatment seeking occurring soon after (115). In 
the present study illegal methadone use tends to be associated 
with the abuse of analgesics, rather than heroin, at least for 
female heroin addicts. Also in this case, a possible explanation 
may be that of an attempt to self-medicate their addiction in 
subjects who will later apply for actual treatment in a 
therapeutic setting. In other words, treatment-seeking female 
heroin addicts may substitute cheaper and more available 
opiates for heroin, possibly combining them with sedatives or 
benzodiazepines, in the attempt to deal with their addiction or 
withdrawal states. Interestingly, male addicts do not seem to 
engage in such a substitutive pattern but tend to maintain 
traditional polyabuse (stimulants, cannabis, alcohol). Also, our 
data do not confirm benzodiazepine abuse to be more relevant 
for male addicts (7). 
As for alcohol abuse alone, no gender-related difference 
emerged. Nevertheless, alcohol is featured within the polyabuse 
pattern (derived from the factorial analysis) on which males 
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score higher. Therefore, our data go along with previous 
findings of greater proneness to alcohol use by male heroin 
addicts (54,58). 
Cannabis is also more likely to be abused by males, in 
agreement with previous findings (58) while cocaine abuse 
does not appear to be gender-related, in contrast to what other 
authors have indicated (23). Nevertheless, women do abuse 
methamphetamines to a greater extent, as a trend. Our 
population of treatment-seeking heroin addicts appears to be 
systematically engaged in polyabuse, by three alternative 
patterns. These three patterns differ from one another: the 
mixed polyabuse pattern features alcohol and illegal drugs, with 
a strong correlation between levels of polyabuse and levels of 
heroin consumption, and a minor correlation with street 
methadone and opiate analgesics. The second abuse pattern 
features opiate analgesics, tranquillizers and sedative drugs, 
with no relation to heroin consumption levels, but a certain link 
with street methadone use. The third pattern includes ketamine 
and inhalants, excluding opiate analgesics and street 
methadone, and with an inverse relationship to heroin 
consumption. The first patterns is rather typical of males, the 
second one of females and the third one has no link with  
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gender. Females addicts tend to be more heterogeneous in their 
substance choice, which is less predictable, whereas one male 
stereotype is definable along the first factor (specific and of 
significant weight). Therefore, different factors, either 
biological or social, may account for such heterogeneity among 
female addicts, beyond gender-related features. The greater 
clash between a violent and aggressive drug-related lifestyle 
and traditional female roles may account for greater depressant 
and ketamine use, in order to buffer gender-specific 
psychological stress. 
Women may be seen as ―low risk‖ addicts or more reasonable 
drug users and be allowed a higher number of prescriptions or 
supplies or convince others to illegally give them legal drugs. 
On the whole, female heroin addicts tended to detach from 
illegal substances before seeking treatment. Such behavior is 
not clearly interpretable: one possible explanation is that 
hormonal factors contribute to amplify neuroendocrine 
functions impaired by fast-acting opiates (heroin), thus 
increasing the need for slow-acting and stable cross-reacting 
drugs (methadone, painkillers). In that case, switching to abuse 
of depressants and other opiates would mirror a higher level of 
opioid disregulation as a prelude to seeking treatment. 
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A second hypothesis is that female patterns of psychiatric 
comorbidity (a higher rate of anxiety disorders) (10,45) and a 
higher level of dysthymia combined with cyclothymia (6; 39; 
33) are specifically sensitive to the action of slow-acting 
opiates.  
Another hypothesis is that remaining in the drug-related 
environment is more distressing for women, who also have a 
lower rate of antisocial personality traits (39). 
On the whole, women may count on greater social acceptance 
of drug-seeking behaviors, and exploit that gender-related 
prejudice to keep away from a street environment for as long as 
possible. When it is no longer possible, depressant and inhalant 
substance use may be a way of coping with these gender-
specific stresses. Thus, different stages may correspond to 
different polyabuse patterns. So, Addiction is one such disease 
that appears to have sex-specific
 
traits and vulnerabilities that 
may be linked to stress. Sex
 
differences are noted in the rate of 
escalation of
 
drug use in which women tend to increase their 
drug intake more
 
rapidly than men. 
Lastly, it may be that women just reach a breaking point with 
addictive behaviors earlier, for a combination of reasons, and 
spontaneously switch to a pattern of self-handled abuse which 
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is a step towards treatment, since it is conceived as an attempt 
to balance opioid functions by tonic drugs. Otherwise, 
treatment-seeking heroin addicts apply for treatment in a typical 
state of poly-intoxication, which indicates deeper engagement 
in self-stimulation by fast-acting drugs. 
Apart from patterns of polyabuse, other addictive features 
(mode, phase of illness, psychosocial stress, periodic abstinence 
and frequency of use) did not differ according to gender 
in our population. 
 
CONCLUSION 
 
The main limitation of this study is that it relies on an analysis 
of subjects at the point they choose to enter a treatment 
program. Exactly how their conditions may mirror those 
patients in the general population is obviously unclear. Within 
the group of those who do not make it to clinical observation 
are those who may actually overdose and die from their illicit 
use of opioid substances. This may be particularly important in 
those patients who combine street methadone with opioid pain  
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killers (in this study predominantly a female pattern), who more 
easily make mistakes in the amount of substances that is safe to 
ingest. Therefore certain patients may not make it into this 
study because of differential effects on their long-term 
availability and longevity. 
Some reported data has suggested that gender does not have a 
definite influence on heroin addiction with respect to patterns of 
substance abuse. Nevertheless, female heroin addicts who apply 
for treatment display a trend towards the use of substitutive 
opiate drugs, such as prescription painkillers and street 
methadone, possibly combined with depressants. Such behavior 
may lead to a relative stabilization due to fast-acting use of 
opioid-related substances, and maybe a partial craving control 
with resultant diminished discomfort. This pattern is rarely 
encountered in males who maintain heroin use, often times 
combined with cannabis or polysubstances. 
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TABLES 
Table 1. Demographic characteristics of 368 heroin addicts at first treatment 
according to gender 
  TotalN=368 MalesN=271 FemaleN=97   
 Missing N (%) N (%) N (%) chi p 
Civil status 
Single 
Married 
Divorced 
  
251 (68.2) 
99 (26.9) 
18 (4.9) 
 
192 (70.8) 
71 (26.2) 
8 (3.0) 
 
59 (60.8) 
28 (28.9) 
10 (10.3) 9.14 0.010 
Occupation 
Student 
White collars 
Blue collars 
Unemployed 
  
43 (11.7) 
91 (24.7) 
123 (33.4) 
111 (30.2) 
 
23 (8.5) 
72 (26.6) 
104 (38.4) 
72 (26.6) 
 
20 (20.6) 
19 (19.6) 
19 (19.6) 
39 (40.2) 22.35 0.00006 
Welfare benefit 
Yes 
  
6 (1.6) 
 
4 (1.5) 
 
2 (2.1) 0.15 0.695 
Parental 
occupation° 
White collars 
Blue collars 
Unemployed 
  
174 (48.6) 
156 (43.6) 
28 (7.8) 
 
119 (45.4) 
127 (48.5) 
16 (6.1) 
 
55 (57.3) 
29 (30.2) 
12 (12.5) 
11.08 0.003 
Income     0.03 0.847 
Poor 36 (9.8) 27 (10.4) 9 (9.3) 
Birth Geo Area 
Northern Italy 
Central Italy 
Southern Italy 
  
92 (25.0) 
222 (60.3) 
54 (14.7) 
 
70 (25.8) 
153 (56.5) 
48 (17.7) 
 
22 (22.7) 
69 (71.1) 
6 (6.2) 
9.30 
 
 
 
 
 
0.009 
 
Birth Location°° 
Primarily urban 
Primarily suburban 
Primarily rural 
 
 
 
TOTAL 
206 (56.6) 
156 (42.9) 
2 (0.5) 
 
M.   
146 (54.5) 
121 (45.1) 
1 (0.4) 
 
F. 
60 (62.5) 
35 (36.5) 
1 (1.0) 2.62 0.269 
Current  Geo Area 
Northern Italy 
Central Italy 
Southern Italy 
  
118 (32.1) 
223 (60.6) 
27 (7.3) 
 
91 (33.6) 
153 (56.5) 
27 (10.0) 
 
27 (27.8) 
70 (72.2) 
0 (0) 13.30 0.001 
Current Location°°° 
Primarily urban 
Primarily suburban 
Primarily rural 
4  
232 (63.7) 
128 (35.2) 
4 (1.1) 
 
166 (61.9) 
98 (36.6) 
4 (1.5) 
 
66 (68.8) 
30 (31.3) 
0 (0) 2.51 0.284 
Living situation°°°° 
Alone 
In family 
1  
38 (10.4) 
329 (89.6) 
 
25 (9.3) 
245 (90.7) 
 
13 (13.4) 
84 (86.4) 1.31 0.250 
   
M±sd  
 
M±sd 
 
M±sd T p 
 *269M/97F 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age (years) 
  
28±7 
(16-51) 
29±7 26±7 2.95 0.004 
 
Education (years)* 
  
9±3 
(0-22) 
 
9±3 
 
9±2 
 
-0.61 
 
0.543 
 Table 2. Presence of related somatic diseases (RSD) of 368 heroin addicts at 
first treatment according to gender. N°RSD refers to patients with almost one 
somatic disease 
 
  Total Males Females   
 Missing N (%) N (%) N (%) chi p 
Absence of RSD  160 (43.5) 123 (45.4) 37 (38.1) 1.52 0.216 
Hepatic 8 132 (36.7) 96 (36.4) 36 (37.5) 0.03 0.843 
Vascolar 4 10 (2.8) 6 (2.3) 4 (4.2) 0.95 0.327 
Gastrointestinal 2 38 (10.4) 26 (9.7) 12 (12.4) 0.56 0.453 
Sexual 2 19 (5.2) 15 (5.6) 4 (4.1) 0.30 0.580 
Dental 2 79 (21.6) 57 (21.2) 22 (22.7) 0.09 0.759 
Lymphadenitis 5 31 (8.5) 21 (7.9) 10 (10.3) 0.53 0.466 
HIV+ 23 30 (8.7) 21 (8.4) 9 (9.5) 0.09 0.751 
AIDS 76 9 (3.1) 7 (3.1) 2 (2.9) 0.00 0.938 
  M±sd (range) M±sd M±sd T p 
N° RSD*  1.67±1.0 
(1-6) 
1.68±1.0 1.65±0.9 0.22 0.828 
*148M/60F    
 
 
 
 
 
 
 
 
 
 
 
Table 3. Mental Status of 368 heroin addicts at first treatment according to 
gender. N°PSYS (Psychophatological Symptoms) refers to symptomatic 
patients 
 
  Total Males Females   
 Missing N (%) N (%) N (%) chi p 
Absence of PSYS 0 139 (37.8) 104 (38.4) 35 (36.1) 0.15 0.689 
Illness Awareness 4 104 (28.6) 85 (31.6) 19 (19.6) 5.22 0.022 
Consciousness 3 32 (8.8) 23 (8.6) 9 (9.3) 0.04 0.835 
Memory 5 45 (12.4) 33 (12.4) 12 (12.5) 0.00 0.971 
Anxiety 4 130 (35.7) 89 (33.3) 41 (42.3) 2.47 0.115 
Depressed mood 4 143 (39.3) 97 (36.3) 46 (17.4) 3.67 0.055 
Sleep disturbances 3 100 (27.4) 74 (27.6) 26 (26.8) 0.02 0.878 
Eating disturbances 3 50 (13.7) 31 (11.6) 19 (19.6) 3.87 0.049 
Excitement 4 80 (22.0) 54 (20.1) 26 (27.1) 1.98 0.159 
Violence 4 75 (20.6) 49 (18.4) 26 (26.8) 3.10 0.077 
Suicidality 4 34 (9.3) 22 (8.2) 12 (12.4) 1.43 0.231 
Delusions 2 22 (6.0) 14 (5.2) 8 (8.2) 1.16 0.279 
Hallucination 5 13 (3.6) 9 (3.4) 4 (4.1) 0.11 0.736 
  M±sd (range) M±sd M±sd T p 
N° PSYS*  3.61±2.4 
(1-12) 
3.47±2.5 4.00±2.0 -1.61 0.110 
* 167M/62F 
 
 
 
 
 
 
 
  
Table 4. Pattern of Abuse in 1,090 Heroin Addicts at Treatment Entry 
 
 Males(N=831) 
N % 
Females(N=259) 
N % 
chi 
Heroin Intake    
Sporadic 112 (13.5) 22 (8.5)  
Weekly              22 (2.6) 9 (3.5)  
Multiple Times for Week             59 (7.1) 14 (5,4)  
Daily 361 (43.4) 112 (43.2)  
More than Once per Day 277 (33.3) 102 (39.4)                7.39 
Modality of Use*    
Stable 498(59.9) 163 (62.9)  
Junkies 177 (21.3) 52 (20.1)  
Two Worlders 111(13.4) 34 (13.1)  
Loners   45 (5.4) 10 (3.9)                 1.38 
Clinical Phase**    
Honey moon  55 (6.6) 18 (6.9)  
Increasing Doses   139 (16.7) 53 (20.5) 
 
 
Revolving Door     637 (76.7) 188 (72.6) 2.02 
Psychosocial Stressors before 
using Heroin    
88 (10.6) 26 (10.0) 0.06 
Periodic   Self- Detoxification  661 (79.5) 201 (77.6) 0.44 
 
 
 
 
 
 
 
N
o
t
e
:No significant gender-related differences were found. 
*Modality of use: Stable = patients maintain a certain level of work and social adjustment, and have legal 
incomes, despite suffering major impairment in leisure time and interpersonal fields. Junky = patients are 
prominently engaged in street life and have illegal incomes from criminal activities, while not working on a 
regular basis, not living with families and not caring for their general health. Two Worlder = patients maintain a 
veneer of adjustment, but are also deeply engaged in illegal activities, in a double-faced lifestyle. Their behavior 
is highly unpredictable, and can quite dangerous socially to others due to their deceptive appearances. Loner = 
patients avoid dealing with other addicts, usually with paranoid thoughts or other forms of social anxiety, so that 
their engagement in the world of addiction is marginal. 
**Clinical Phase: Honeymoon = starting phase of addiction, during which drug-related pleasure is still relevant, 
so that increasing engagement in drug use seems justified, and social adjustment is not lost yet. Increasing 
Doses = tolerance develops but patient does not react by detoxifying, but resorts to higher dosages to chase 
drug-related euphoria, at the expense of social adjustment. Revolving Door = addiction remains through 
relapses, while the latency of relapse is shorter and the automaticity of craving no longer requires 
reinforcement. 
 
 
 
 
 
 
 
Table 5. Substance Abuse in 1,090 Heroin Addicts at Treatment Entry 
 
 
 
 
   Males (N = 831)      Females (N = 259)       chi 
N %      N % 
 
               Opioid Painkiller 85 (10.2)                             26 (10.0)             0.00 
                                           Heroin                           757 (91.1)               219 (84.6)        9.01** 
                Illegal Methadone  152 (18.3)                         68 (26.3)         7.77** 
                                           Alcohol                287 (34.5)                         82 (31.7           0.72 
                                           Ketamine   13 (1,6)                            11 (4.2)           6.59* 
                                           Benzodiazepines  216 (26,0)                         84 (32.4)         4.10* 
Hypnotics   176 (21.2)                         73 (28.2)        5.49* 
                                          Cocaine    465 (56.0)   133 (51.4)  1.69 
                                          Amphetamines   253 (30.4)   103 (39.8)  7.80** 
                                          LSD    248 (29.8)   63 (24.3)  2.94 
Cannabinoids  537 (64.6)   148 (57.1)  4.75* 
                                           Inhalants     30 (3.6)    15 (5.8)   2.37 
                                           Polyabuse   309 (37.2)   95 (36.7)  0.02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6:  Factor Analysis 
 
Heroin    Hypnotics   Inhalants 
Stimulants  Benzodiazepines  Anesthetics  
Cannabinoids    Painkillers 
 
 
 
Opioid painkiller .    -00 .  57     .27 
Heroin .     54   -.00     -.16 
Illegal Methadone .   33 .  25 .    15 
Alcohol .     43 .  23     -.02 
Ketamine     .02   .09     .79 
Benzodiazepines     .25   .79     -.00 
Hypnotics .    17 .  84 .    02 
Cocaine .     76   .17 .    13 
Amphetamines .    60 .  36 .    27 
LSD .     67 .  17     .26 
Cannabinoids .    78   -.00     .02 
Inhalants .    10   .09     .79 
Eingenvalue     3.68   1.40     1.15 
Variance     30.7   11.7    9.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
